Perrigo (PRGO)

• Market cap: $3.42B
• 1 day: 0.00%
• 5 days: 1.29%
• 1 month: -0.91%
• 3 months: -1.26%
• 6 months: -12.58%
• Year to date: -3.50%
• 1 year: -21.67%
• 5 years: -57.82%
• 10 years: -83.44%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Employees: 9,140

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

390% more call options, than puts

Call options by funds: $54.2M | Put options by funds: $11.1M

7% more repeat investments, than reductions

Existing positions increased: 131 | Existing positions reduced: 123

3% more capital invested

Capital invested by funds: $3.35B [Q2] → $3.44B (+$90.3M) [Q3]

0.46% more ownership

Funds ownership: 95.72% [Q2] → 96.18% (+0.46%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 9 [Q2] → 9 (+0) [Q3]

3% less funds holding

Funds holding: 355 [Q2] → 343 (-12) [Q3]

19% less first-time investments, than exits

New positions opened: 42 | Existing positions closed: 52

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $27 8% upside
• Avg. target: $27 8% upside
• High target: $27 8% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Piper Sandler Korinne Wolfmeyer 40% 1-year accuracy 19 / 47 met price target

8% upside $27

Neutral Downgraded

6 Jan 2025